New Federal Incentives for Diversity in Clinical Trials

被引：34

作者：

Hwang, Thomas J. ^{[1
,2
]}

Brawley, Otis W. ^{[3
,4
]}

机构：

[1] Brigham & Womens Hosp, Div Urol Surg, 75 Francis St, Boston, MA 02115 USA

[2] Dana Farber Canc Inst, Canc Innovat & Regulat Initiat, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA

[3] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[4] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2022年 / 387卷 / 15期

关键词：

D O I：

10.1056/NEJMp2209043

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

New Federal Incentives for Diversity in Trials Recent House legislation would codify recommendations that trial sponsors design diversity plans for enrollment, but it does not provide a mechanism for remedying inadequate progress.

引用

页码：1347 / 1349

页数：3

共 4 条

[1] Bibbins-Domingo K., 2022, Improving representation in clinical trials and research: building research equity for women and underrepresented groups
[2] Food and Drug Administration, 2022, DIV PLANS IMPR ENR P
[3] Government Accountability Office, 2020, DRUG DEV FDAS PRIOR
[4] Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018
Loree, Jonathan M.
Anand, Seerat
Dasari, Arvind
Unger, Joseph M.
Gothwal, Anirudh
Ellis, Lee M.
Varadhachary, Gauri
Kopetz, Scott
Overman, Michael J.
Raghav, Kanwal
[J]. JAMA ONCOLOGY, 2019, 5 (10)

← 1 →